Good practices for 89Zr radiopharmaceutical production and quality control

Thomas Erik Wuensche,Serge Lyashchenko,Guus A. M. S. van Dongen,Danielle Vugts

DOI: https://doi.org/10.1186/s41181-024-00258-y

2024-05-13

EJNMMI Radiopharmacy and Chemistry

Abstract:During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in preclinical and clinical drug development and patient selection, primarily due to its advantageous physical properties that allow straightforward radiolabeling of antibodies ( 89 Zr-immuno-PET). The extended half-life of 78.4 h permits flexibility with respect to the logistics of tracer production, transportation, and imaging and allows imaging at later points in time. Additionally, its relatively low positron energy contributes to high-sensitivity, high-resolution PET imaging. Considering the growing interest in radiolabeling antibodies, antibody derivatives, and other compound classes with 89 Zr in both clinical and pre-clinical settings, there is an urgent need to acquire valuable recommendations and guidelines towards standardization of labeling procedures.